08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal was...
07:00 , Jul 9, 2007 |  BC Week In Review  |  Company News

Avanir Pharmaceuticals, Azur Pharma sales and marketing update

AVNR will sell worldwide rights to schizophrenic treatment FazaClo clozapine to Azur. AVNR will receive $42 million up front and is eligible for $10 million in milestones, plus up to $2 million in royalties....
07:00 , May 29, 2006 |  BC Week In Review  |  Company News

Alamo Pharmaceuticals, Avanir Pharmaceuticals deal

AVNR acquired Alamo for $4 million in cash plus $25 million in three-year notes. The deal gives AVNR a 50-person salesforce that the company plans to use for Neurodex to treat pseudobulbar affect (PBA)....
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

Alamo Pharmaceuticals management update

Alamo Pharmaceuticals LLC, Beverly Hills, Calif.   Business: Neurology   Hired: Paul Duffy as EVP, formerly national director of neuroscience sales, psychiatry, at Novartis SA   ...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

Alamo Pharmaceuticals, Cima sales and marketing update

Alamo launched its Fazaclo orally disintegrating formulation of clozapine to treat severe schizophrenia in patients who fail to respond to standard drug treatment. The drug incorporates CIMA's OraSolv technology, and CIMA will manufacture the...
08:00 , Mar 15, 2004 |  BC Week In Review  |  Clinical News

Fazaclo clozapine regulatory update

CIMA said the FDA approved Alamo's Fazaclo to treat severe schizophrenia in patients who fail to respond to standard drug treatment. CIMA will manufacture the orally disintegrating tablet formulation for Alamo in exchange for manufacturing...